Sirio Pharma receives sports nutrition production licence approval18 Feb 2019
The approval enables Sirio to add special sports nutrition ingredients into products and covers six functional classes for ‘protein supplementary’, ‘speed & power’, ‘endurance’, ‘energy control’, ‘energy supplementary’, and ‘post-exercise recovery’.
Sirio Pharma – a global nutraceutical CDMO – has been granted SC (production licence) of sports nutrition food in China.
The approval enables Sirio to add special sports nutrition ingredients into products and covers six functional classes for ‘protein supplementary’, ‘speed & power’, ‘endurance’, ‘energy control’, ‘energy supplementary’, and ‘post-exercise recovery’. Due to the stringency of regulations and complexity of achieving approval, Sirio is now one of just seven approved licence holders in the country.
“In the last few years, sports nutrition in China has grown extremely quickly – at a CAGR of 37% between 2013 and 2017 – and is forecast to continue to expand at up to 50% per year, easily outstripping growth in the US and other global markets. So it is a huge opportunity not only for domestic companies, but also international brands,” commented Rui Yang, CSO of SIRIO Pharma.
Until recently, the barriers to entry for international brands in China were high, and the majority entered the market using cross-border e-commerce. However, Sirio’s new sports licence – coupled with its strong formulation capabilities and capacity – now provide the possibility of contract manufacturing these products in China and selling through all distribution channels across the country. Potentially opening-up a far larger customer base. It also enables international brands to start developing customized sports nutrition products that are tailored to local consumer preferences in China.
Significantly, the licence allows nutra brands to make specific functional claims on sports nutrition product labeling, and will cover popular ingredients including concentrated whey protein, whey protein isolate, soy protein isolate: BCAA, CaHMB, creatine, and many vitamin & minerals.
Yang added: “The consumer demand for sports products in China has exploded in the last few years, in part thanks to the national fitness policy, yet the production and regulatory environment is still maturing. As a result, only a very small number of companies have licences and, through Sirio, we foresee tremendous opportunities for brand companies to access one of the fastest growing segments of the nutrition industry globally. In fact, we have already had a number of enquiries and we are able to start production immediately. What is more, for established brands who want to build their name in the China, by partnering with Sirio, they are now even able to develop completely unique products tailored to the Chinese sports consumer.”
The new sports production licence has been introduced to better regulate manufacturers and combat counterfeit products in China, and involves a rigorous onsite audit covering environmental control, equipment, warehousing and documentation.
Specialist API CDMO acquired by GHO Capital
16 Mar 2019
Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.Read more
Bringing next generation single-use sensor technologies to the life science market
14 Mar 2019
Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.Read more
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy
13 Mar 2019
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.Read more
TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program
12 Mar 2019
Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.Read more
Overcoming lyophilization challenges at Interphex 2019
10 Mar 2019
Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.Read more
Catalent invests over $27 million to commercialize Zydis Ultra
7 Mar 2019
Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.Read more
Novel systems for membrane chromatography
6 Mar 2019
Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.Read more
Lilly to introduce lower-priced insulin
5 Mar 2019
Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.Read more
Biogen acquisition boosts its ophthalmology pipeline
4 Mar 2019
Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.Read more
Uniqsis expands LED photoreactor range
3 Mar 2019
The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation